
Gigi Georgiana Huang
Examiner (ID: 703, Phone: (571)272-9073 , Office: P/1621 )
| Most Active Art Unit | 1613 |
| Art Unit(s) | 1618, 1609, 1612, 1629, 1621, 1617, 1613, 1627 |
| Total Applications | 773 |
| Issued Applications | 215 |
| Pending Applications | 86 |
| Abandoned Applications | 496 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17733210
[patent_doc_number] => 20220218669
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-14
[patent_title] => COMPOSITIONS AND METHODS FOR NON-SURGICAL TREATMENT OF PTOSIS
[patent_app_type] => utility
[patent_app_number] => 17/679278
[patent_app_country] => US
[patent_app_date] => 2022-02-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12310
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17679278
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/679278 | COMPOSITIONS AND METHODS FOR NON-SURGICAL TREATMENT OF PTOSIS | Feb 23, 2022 | Abandoned |
Array
(
[id] => 19111224
[patent_doc_number] => 20240122974
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-18
[patent_title] => TREATMENT OF MYOPIA
[patent_app_type] => utility
[patent_app_number] => 18/546258
[patent_app_country] => US
[patent_app_date] => 2022-02-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8955
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 13
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18546258
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/546258 | TREATMENT OF MYOPIA | Feb 10, 2022 | Pending |
Array
(
[id] => 17774924
[patent_doc_number] => 20220241273
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-04
[patent_title] => USE OF SGC ACTIVATORS FOR THE TREATMENT OF OPHTHALMOLOGIC DISEASES
[patent_app_type] => utility
[patent_app_number] => 17/667418
[patent_app_country] => US
[patent_app_date] => 2022-02-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 42861
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 210
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17667418
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/667418 | USE OF SGC ACTIVATORS FOR THE TREATMENT OF OPHTHALMOLOGIC DISEASES | Feb 7, 2022 | Abandoned |
Array
(
[id] => 19049286
[patent_doc_number] => 20240091255
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-21
[patent_title] => TREATMENT OF ASTIGMATISM
[patent_app_type] => utility
[patent_app_number] => 18/274647
[patent_app_country] => US
[patent_app_date] => 2022-01-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8338
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18274647
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/274647 | TREATMENT OF ASTIGMATISM | Jan 27, 2022 | Pending |
Array
(
[id] => 17593502
[patent_doc_number] => 20220143075
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-12
[patent_title] => OPHTHALMIC PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING OCULAR SURFACE DISEASE
[patent_app_type] => utility
[patent_app_number] => 17/582627
[patent_app_country] => US
[patent_app_date] => 2022-01-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7110
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 40
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17582627
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/582627 | OPHTHALMIC PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING OCULAR SURFACE DISEASE | Jan 23, 2022 | Pending |
Array
(
[id] => 17702692
[patent_doc_number] => 20220202698
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-30
[patent_title] => EXTENDED RELEASE PHARMACEUTICAL COMPOSITIONS OF RIOCIGUAT
[patent_app_type] => utility
[patent_app_number] => 17/562487
[patent_app_country] => US
[patent_app_date] => 2021-12-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12022
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 94
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17562487
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/562487 | EXTENDED RELEASE PHARMACEUTICAL COMPOSITIONS OF RIOCIGUAT | Dec 26, 2021 | Abandoned |
Array
(
[id] => 19903156
[patent_doc_number] => 12280141
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-04-22
[patent_title] => Liquid depot for non-invasive sustained delivery of agents to the eye
[patent_app_type] => utility
[patent_app_number] => 17/547028
[patent_app_country] => US
[patent_app_date] => 2021-12-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 17
[patent_no_of_words] => 9780
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 63
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17547028
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/547028 | Liquid depot for non-invasive sustained delivery of agents to the eye | Dec 8, 2021 | Issued |
Array
(
[id] => 19641276
[patent_doc_number] => 20240415796
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-12-19
[patent_title] => EYEDROPS FOR AMELIORATING OR PREVENTING RETINAL CIRCULATION DISORDER AND RETINAL NEUROVASCULAR COUPLING DISORDER
[patent_app_type] => utility
[patent_app_number] => 18/253096
[patent_app_country] => US
[patent_app_date] => 2021-11-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5492
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18253096
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/253096 | EYEDROPS FOR AMELIORATING OR PREVENTING RETINAL CIRCULATION DISORDER AND RETINAL NEUROVASCULAR COUPLING DISORDER | Nov 18, 2021 | Pending |
Array
(
[id] => 17775056
[patent_doc_number] => 20220241405
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-04
[patent_title] => ALLERGEN DESENSITIZATION METHOD
[patent_app_type] => utility
[patent_app_number] => 17/523648
[patent_app_country] => US
[patent_app_date] => 2021-11-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7785
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17523648
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/523648 | Allergen desensitization method | Nov 9, 2021 | Issued |
Array
(
[id] => 18815945
[patent_doc_number] => 20230390284
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-12-07
[patent_title] => DEGRADANT COMPOUND IN A MEDICANT
[patent_app_type] => utility
[patent_app_number] => 18/250921
[patent_app_country] => US
[patent_app_date] => 2021-11-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20721
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -131
[patent_words_short_claim] => 13
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18250921
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/250921 | DEGRADANT COMPOUND IN A MEDICANT | Nov 1, 2021 | Abandoned |
Array
(
[id] => 18815945
[patent_doc_number] => 20230390284
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-12-07
[patent_title] => DEGRADANT COMPOUND IN A MEDICANT
[patent_app_type] => utility
[patent_app_number] => 18/250921
[patent_app_country] => US
[patent_app_date] => 2021-11-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20721
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -131
[patent_words_short_claim] => 13
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18250921
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/250921 | DEGRADANT COMPOUND IN A MEDICANT | Nov 1, 2021 | Abandoned |
Array
(
[id] => 17398013
[patent_doc_number] => 20220040103
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-10
[patent_title] => EMULSION FORMULATIONS OF MULTIKINASE INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 17/509774
[patent_app_country] => US
[patent_app_date] => 2021-10-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19318
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 29
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17509774
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/509774 | Emulsion formulations of multikinase inhibitors | Oct 24, 2021 | Issued |
Array
(
[id] => 17519252
[patent_doc_number] => 20220105100
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-04-07
[patent_title] => SAFE BRINZOLAMIDE AND BRIMONIDINE COMPOSITIONS WITH ENHANCED BENZALKONIUM CHLORIDE CONTENT
[patent_app_type] => utility
[patent_app_number] => 17/494635
[patent_app_country] => US
[patent_app_date] => 2021-10-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 48675
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 58
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17494635
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/494635 | SAFE BRINZOLAMIDE AND BRIMONIDINE COMPOSITIONS WITH ENHANCED BENZALKONIUM CHLORIDE CONTENT | Oct 4, 2021 | Abandoned |
Array
(
[id] => 17519255
[patent_doc_number] => 20220105103
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-04-07
[patent_title] => SAFE USE OF BRINZOLAMIDE AND BRIMONIDINE COMPOSITIONS WITH ENHANCED BENZALKONIUM CHLORIDE CONTENT
[patent_app_type] => utility
[patent_app_number] => 17/494713
[patent_app_country] => US
[patent_app_date] => 2021-10-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 48687
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 130
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17494713
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/494713 | SAFE USE OF BRINZOLAMIDE AND BRIMONIDINE COMPOSITIONS WITH ENHANCED BENZALKONIUM CHLORIDE CONTENT | Oct 4, 2021 | Abandoned |
Array
(
[id] => 19140374
[patent_doc_number] => 20240139153
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-02
[patent_title] => Inhibition of Endothelial ETS Family Transcription Factors Promotes Flow-Dependent Ocular Vessel Regression
[patent_app_type] => utility
[patent_app_number] => 18/044149
[patent_app_country] => US
[patent_app_date] => 2021-09-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10533
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18044149
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/044149 | Inhibition of Endothelial ETS Family Transcription Factors Promotes Flow-Dependent Ocular Vessel Regression | Sep 14, 2021 | Pending |
Array
(
[id] => 18626616
[patent_doc_number] => 20230285411
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-14
[patent_title] => DRUG FORMULATION CONTAINING SEPETAPROST
[patent_app_type] => utility
[patent_app_number] => 18/040894
[patent_app_country] => US
[patent_app_date] => 2021-08-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7260
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18040894
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/040894 | DRUG FORMULATION CONTAINING SEPETAPROST | Aug 11, 2021 | Pending |
Array
(
[id] => 17355290
[patent_doc_number] => 20220016086
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-20
[patent_title] => COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES
[patent_app_type] => utility
[patent_app_number] => 17/352698
[patent_app_country] => US
[patent_app_date] => 2021-06-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 39903
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17352698
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/352698 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | Jun 20, 2021 | Abandoned |
Array
(
[id] => 18690865
[patent_doc_number] => 20230321024
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-12
[patent_title] => METHODS OF TREATING VISUAL DISORDERS USING DAILY LOW DOSING OF A RETINOID COMPOUND
[patent_app_type] => utility
[patent_app_number] => 17/998370
[patent_app_country] => US
[patent_app_date] => 2021-06-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10532
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17998370
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/998370 | METHODS OF TREATING VISUAL DISORDERS USING DAILY LOW DOSING OF A RETINOID COMPOUND | Jun 7, 2021 | Pending |
Array
(
[id] => 18690865
[patent_doc_number] => 20230321024
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-12
[patent_title] => METHODS OF TREATING VISUAL DISORDERS USING DAILY LOW DOSING OF A RETINOID COMPOUND
[patent_app_type] => utility
[patent_app_number] => 17/998370
[patent_app_country] => US
[patent_app_date] => 2021-06-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10532
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17998370
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/998370 | METHODS OF TREATING VISUAL DISORDERS USING DAILY LOW DOSING OF A RETINOID COMPOUND | Jun 7, 2021 | Pending |
Array
(
[id] => 17586467
[patent_doc_number] => 11324708
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2022-05-10
[patent_title] => Niclosamide formulations for treating disease
[patent_app_type] => utility
[patent_app_number] => 17/330067
[patent_app_country] => US
[patent_app_date] => 2021-05-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 6
[patent_no_of_words] => 49615
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 45
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17330067
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/330067 | Niclosamide formulations for treating disease | May 24, 2021 | Issued |